Company News

Gisela Lorente: “Nuestro enfoque se centra en eldesarrollo de fármacos innovadores para combatir el cáncer”

Academy for Women Entrepreneurs (AWE) es un programa de Foment del Treball, elDepartamento de Estado de Estados Unidos y el Consulado Americano en el que hanpodido participar 30 mujeres emprendedoras. AWE consta de 4 ejes: formación onlinepor parte de la Escuela de negocios Thunderbird de la Universidad de Arizona,Masterclasses presenciales, tours inspiradores y la oportunidad […]

Gisela Lorente: “Nuestro enfoque se centra en eldesarrollo de fármacos innovadores para combatir el cáncer” Read More »

Team Member - Gisela

Gisela Lorente, new CEO of biotechnological company Aptadel Therapeutics

https://aptadeltx.com/wp-content/uploads/2024/02/Nota-de-prensa_CEO_GL_2023.pdf Aptadel Therapeutics – a pre•clinical stage drug development spinoff company of the Bellvitge BiomedicalResearch lnstitute (IDIBELL), based in the Barcelona Science Parkwhich focuses on the development of anew platform for RNA therapies for childhood cancer- has named Gisela Lorente, to date the chie! scientificofficer, as the company’s new CEO.Gisela Lorente is a doctor in

Gisela Lorente, new CEO of biotechnological company Aptadel Therapeutics Read More »

Aptadel Therapeutics awarded Eurostars grant

Aptadel Therapeutics awarded Eurostarsgrant for a first-in-class RNA-basedtargeted therapy for childhood cancer Barcelona, Spain, May, 11th 2022.Aptadel Therapeutics, – together with leading EU biotech companies, iCellate and Anapharm,– has been awarded a Eurostars grant, subsidised by CDTI, for a first in-class RNA Aptamer-based targeted therapyand companion diagnostic for childhood cancer Ewing Sarcoma (ES), to bring

Aptadel Therapeutics awarded Eurostars grant Read More »

Dr. Gisela Lorente, CSO at Aptadel Therapeutics, has been interviewed by Biocat

Startup Generator is the space reserved at Biocat for interviews and reports on startups linked to the bioscience and biotechnology sector. In this interview, Gisela Lorente, Chief Scientific Officer (CSO), explains the need for a good team, the strategic decisions Aptadel Therapeutics has made, and the importance of being motivated and believing in it. She also reveals

Dr. Gisela Lorente, CSO at Aptadel Therapeutics, has been interviewed by Biocat Read More »

Aptadel Therapeutics has participated in the 2021 Richi Entrepreneurs Boston Immersion Program.

2021 Richi Entrepreneurs Boston Immersion Program organized by the RichiFoundation has started this week with a selection of the best start ups in the Spanish Innovation Ecosystem. Aptadel Therapeutics has been presenting its next generation developing therapies for curing childhood and adult cancers at the CIC (Cambridge Innovation Center) in Boston. After 2 weeks of

Aptadel Therapeutics has participated in the 2021 Richi Entrepreneurs Boston Immersion Program. Read More »

Aptadel has been one of the 11 start up selected in the BCN Health Booster programme.

Aptadel has been one of the 11 start up selected in the BCN Health Booster programme aimed at companies in the health sector to be accelerated by accessing a laboratory in the Parc Científic de Barcelona. Today our scientific advisor Oscar Martinez Tirado and our CSO Gisela Lorente have participated in the award ceremony lead by Ajuntament de Barcelona,

Aptadel has been one of the 11 start up selected in the BCN Health Booster programme. Read More »

Aptadel Team

Aptadel Therapeutics settles in the Barcelona Science Park and raises $2.1M in Seed Financing Round.

Aptadel Therapeutics, a pre-clinical biomedical company focused on developing a RNA-based platform of targeted therapy delivery to treat cancer, announces the closing of a $2.1M in seed financing. As part of its expansion strategy, the company has also just established its headquarters at the Barcelona Science Park. Aptadel Therapeutics, founded by Dr Oscar Martinez-Tirado of the Bellvitge

Aptadel Therapeutics settles in the Barcelona Science Park and raises $2.1M in Seed Financing Round. Read More »